|
| 37163373 | MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells. | Cell Rep | 2023 |
| 37441939 | Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. | Eur J Cancer | 2023 |
| 35978693 | Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8<i>H</i>-purin-8-one Inhibitors of DNA-PK. | ACS Med Chem Lett | 2022 |
| 36241868 | AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. | Oncogene | 2022 |
| 36289203 | Clonal somatic copy number altered driver events inform drug sensitivity in high-grade serous ovarian cancer. | Nat Commun | 2022 |
| 34011558 | Inhibition of DNA-PK with AZD7648 Sensitizes Tumor Cells to Radiotherapy and Induces Type I IFN-Dependent Durable Tumor Control. | Clin Cancer Res | 2021 |
| 33742147 | Olaparib increases the therapeutic index of hemithoracic irradiation compared with hemithoracic irradiation alone in a mouse lung cancer model. | Br J Cancer | 2021 |
| 33495510 | Design and optimisation of dendrimer-conjugated Bcl-2/x<sub>L</sub> inhibitor, AZD0466, with improved therapeutic index for cancer therapy. | Commun Biol | 2021 |
| 32220884 | Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. | Clin Cancer Res | 2020 |
| 31851518 | The Discovery of 7-Methyl-2-[(7-methyl[1,2,4]triazolo[1,5-<i>a</i>]pyridin-6-yl)amino]-9-(tetrahydro-2<i>H</i>-pyran-4-yl)-7,9-dihydro-8<i>H</i>-purin-8-one (AZD7648), a Potent and Selective DNA-Dependent Protein Kinase (DNA-PK) Inhibitor. | J Med Chem | 2020 |
| 32917731 | Expression of Concern: Mechanisms underlying p53 regulation of <i>PIK3CA</i> transcription in ovarian surface epithelium and in ovarian cancer. | J Cell Sci | 2020 |
| 32988967 | AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia. | Clin Cancer Res | 2020 |
| 30459156 | Preclinical Evaluation of AZ12601011 and AZ12799734, Inhibitors of Transforming Growth Factor <i>β</i> Superfamily Type 1 Receptors. | Mol Pharmacol | 2019 |
| 31699977 | AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity. | Nat Commun | 2019 |
| 29066505 | A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in <i>PIK3CA</i>-Mutated Breast and Gynecologic Cancers. | Clin Cancer Res | 2018 |
| 30254068 | Optimizing the design of population-based patient-derived tumor xenograft studies to better predict clinical response. | Dis Model Mech | 2018 |
| 28008155 | Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors. | Oncotarget | 2017 |
| 28202458 | Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL. | Blood | 2017 |
| 29084756 | Akt inhibition improves long-term tumour control following radiotherapy by altering the microenvironment. | EMBO Mol Med | 2017 |
| 29262536 | Delineating the distinct role of AKT in mediating cell survival and proliferation induced by CD154 and IL-4/IL-21 in chronic lymphocytic leukemia. | Oncotarget | 2017 |
| 28915623 | Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer. | Oncotarget | 2017 |
| 28556895 | A pharmacokinetic-pharmacodynamic model predicting tumour growth inhibition after intermittent administration with the mTOR kinase inhibitor AZD8055. | Br J Pharmacol | 2017 |
| 26824321 | Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma. | Oncotarget | 2016 |
| 27550940 | Identification of Pharmacodynamic Transcript Biomarkers in Response to FGFR Inhibition by AZD4547. | Mol Cancer Ther | 2016 |
| 26989080 | Identification of differential PI3K pathway target dependencies in T-cell acute lymphoblastic leukemia through a large cancer cell panel screen. | Oncotarget | 2016 |
| 26936079 | Using Automated Image Analysis Algorithms to Distinguish Normal, Aberrant, and Degenerate Mitotic Figures Induced by Eg5 Inhibition. | Toxicol Pathol | 2016 |
| 26910118 | Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer. | Oncotarget | 2016 |
| 25151012 | Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models. | Eur Urol | 2015 |
| 26358751 | AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules. | Mol Cancer Ther | 2015 |
| 26351323 | Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors. | Mol Cancer Ther | 2015 |
| 26267320 | Development and exploitation of a novel mutant androgen receptor modelling strategy to identify new targets for advanced prostate cancer therapy. | Oncotarget | 2015 |
| 26095475 | Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models. | Int J Oncol | 2015 |
| 26092323 | Validation of a predictive modeling approach to demonstrate the relative efficacy of three different schedules of the AKT inhibitor AZD5363. | Cancer Chemother Pharmacol | 2015 |
| 26116361 | AKT Antagonist AZD5363 Influences Estrogen Receptor Function in Endocrine-Resistant Breast Cancer and Synergizes with Fulvestrant (ICI182780) In Vivo. | Mol Cancer Ther | 2015 |
| 25220373 | High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models. | Eur Urol | 2015 |
| 25398829 | Inhibition of PI3Kβ signaling with AZD8186 inhibits growth of PTEN-deficient breast and prostate tumors alone and in combination with docetaxel. | Mol Cancer Ther | 2015 |
| 24975213 | PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. | Br J Haematol | 2014 |
| 25212826 | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. | Breast Cancer Res | 2014 |
| 23344784 | 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography demonstrates target inhibition with the potential to predict anti-tumour activity following treatment with the AKT inhibitor AZD5363. | Mol Imaging Biol | 2013 |
| 24130073 | The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer. | Clin Cancer Res | 2013 |
| 24088382 | The AKT inhibitor AZD5363 is selectively active in PI3KCA mutant gastric cancer, and sensitizes a patient-derived gastric cancer xenograft model with PTEN loss to Taxotere. | J Transl Med | 2013 |
| 23844554 | Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. | Breast Cancer Res | 2013 |
| 23966621 | Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. | Mol Cancer Ther | 2013 |
| 23394218 | Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases. | J Med Chem | 2013 |
| 23581296 | Elevated SGK1 predicts resistance of breast cancer cells to Akt inhibitors. | Biochem J | 2013 |
| 23258740 | Blocked autophagy using lysosomotropic agents sensitizes resistant prostate tumor cells to the novel Akt inhibitor AZD5363. | Clin Cancer Res | 2013 |
| 22343622 | The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models. | Br J Cancer | 2012 |
| 22895070 | Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. | Cancer Biol Ther | 2012 |
| 22248236 | Diverse heterocyclic scaffolds as allosteric inhibitors of AKT. | J Med Chem | 2012 |
| 22271687 | Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055). | Cancer Res | 2012 |